(19)
(11) EP 2 927 224 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
19.12.2018 Bulletin 2018/51

(45) Mention of the grant of the patent:
03.10.2018 Bulletin 2018/40

(21) Application number: 15158267.3

(22) Date of filing: 13.10.2011
(51) International Patent Classification (IPC): 
C07D 401/14(2006.01)
C07D 413/14(2006.01)
A61K 31/551(2006.01)
 C07D 405/14(2006.01)
C07D 417/14(2006.01)
A61P 29/00(2006.01)

(54)

Receptor antagonists

Rezeptorantagonisten

Antagonistes du récepteur LPA

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 14.10.2010 GB 201017345

(43) Date of publication of application:
07.10.2015 Bulletin 2015/41

(62) Application number of the earlier application in accordance with Art. 76 EPC:
11773227.1 / 2627649

(73) Proprietor: PROXIMAGEN, LLC
Plymouth, MN 55441 (US)

(72) Inventors:
  • Brown, Giles
    London, EC1M 3LN (GB)
  • Higginbottom, Michael
    London, EC1M 3LN (GB)
  • Stewart, Alison
    London, EC1M 3LN (GB)
  • Patient, Lee
    London, EC1M 3LN (GB)
  • Carley, Allison
    London, EC1M 3LN (GB)
  • Simpson, Iain
    London, EC1M 3LN (GB)
  • Savory, Edward
    London, EC1M 3LN (GB)
  • Oliver, Kathryn
    London, EC1M 3LN (GB)
  • Cole, Andrew Graham
    Cranbury, NJ 08512 (US)

(74) Representative: Gill Jennings & Every LLP 
The Broadgate Tower 20 Primrose Street
London EC2A 2ES
London EC2A 2ES (GB)


(56) References cited: : 
WO-A1-01/14333
WO-A1-2008/079279
 WO-A1-2006/071875
WO-A1-2010/054006
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).